RMD
ResMedPrevious close
229.94
Change
−22.89 / −9.05%
P/E (TTM) ?
21.5
Market Cap
$32.6B
1M
+4.00%
S&P 500 −0.91% over same period
Volume / Avg Volume
3.5M / 1.1M
3.03× average
Latest earnings analysisFY2026 Q4Reported 2026-07-07
ResMed FY2026: revenue up 10% to $5.65 billion, non-GAAP EPS up 17%
ResMed closed fiscal 2026 with 10.0% revenue growth to $5.65 billion and a 17.0% rise in non-GAAP earnings per share, so the core sleep and breathing franchise is compounding while margins widen. The fourth quarter looks messier on the GAAP line because $41.9 million of Astral field safety notification expenses landed in cost of sales. Read the quarter through non-GAAP gross margin, which still rose to 62.3%.
Read the full analysis →Revenue$5.65BYoY +319.40%
EPS (non-GAAP)$2.95Beatest. $2.92
Next-day move−6.33%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q4 Quarter ended 2026-06 | 2026-07-07 | $5.7B | Read analysis → |
| FY2026 Q3 Quarter ended 2026-03 | 2026-04-30 | $1.4B | Pending |
| FY2026 Q2 Quarter ended 2025-12 | 2026-01-29 | $1.4B | Pending |
| FY2026 Q1 Quarter ended 2025-09 | 2025-10-30 | $1.3B | Pending |
| FY2025 Q4 Quarter ended 2025-06 | 2025-07-31 | $5.1B | Pending |
| FY2025 Q3 Quarter ended 2025-03 | 2025-04-24 | $1.3B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 11 of its 5-year rangeCheap
5-year range 19.9 – 35.1 · Median 27.9
Last 4 quarters: $1.5B in buybacks + $357M in dividends, 5.65% of market cap combined
P/E (TTM)
21.5
P/B
5.0
P/S
5.8
Dividend Yield
1.25%
Earnings Reaction
Over the last 6 reports, the stock moved ±2.6% on average on the first trading day after, rising 2 times
Most recent −6.33%
Volatility & Correlation
1-year beta 0.47 · Correlation with S&P 500 0.20Low beta
Annualized volatility 30% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 6 · $5.4MNet selling $5.4M
- 10-23Rider Michael JGlobal General CounselSell$0.10M400 shares · Avg price 255.00
- 10-07Farrell Michael J.Chairman and CEOSell$1.1M4,991 shares · Avg price 226.33
- 09-08Farrell Michael J.Chairman and CEOSell$1.1M4,991 shares · Avg price 222.44
- 09-02FARRELL PETER CDirectorSell$0.23M970 shares · Avg price 234.73
- 08-07Farrell Michael J.Chairman and CEOSell$1.0M4,991 shares · Avg price 205.69
- 08-05FARRELL PETER CDirectorSell$1.8M8,000 shares · Avg price 225.00
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2027 Q1 | 1.41 | +5.9% | 61.5% | 0.42 | 2.92 |
| FY2026 Q4 | 1.46 | +8.6% | 59.1% | 0.38 | 2.64 |
| FY2026 Q3 | 1.43 | +10.8% | 62.2% | 0.40 | 2.74 |
| FY2026 Q2 | 1.42 | +11.0% | 61.8% | 0.39 | 2.68 |
| FY2026 Q1 | 1.34 | +9.1% | 61.2% | 0.35 | 2.37 |
| FY2025 Q4 | 1.35 | +10.2% | 60.8% | 0.38 | 2.58 |
| FY2025 Q3 | 1.29 | +7.9% | 59.3% | 0.37 | 2.48 |
| FY2025 Q2 | 1.28 | +10.3% | 58.6% | 0.34 | 2.34 |
| FY2025 Q1 | 1.22 | +11.1% | 58.6% | 0.31 | 2.11 |
| FY2024 Q4 | 1.22 | +9.0% | 58.5% | 0.29 | 1.97 |
| FY2024 Q3 | 1.20 | +7.2% | 57.9% | 0.30 | 2.04 |
| FY2024 Q2 | 1.16 | +12.5% | 55.6% | 0.21 | 1.42 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| RMD | 21.5 | +5.9% | 61.5% | +4.00% | Bullish |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |